Live Breaking News & Updates on ப்ரோஸ்பெக்டிவ் கூட்டுறவு

Stay updated with breaking news from ப்ரோஸ்பெக்டிவ் கூட்டுறவு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome


Home / Top News / Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome
Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome
SAN DIEGO, Calif., March 01, 2021 (GLOBE NEWSWIRE) Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered into an exclusive licensing term sheet with Aardvark Therapeutics (“Aardvark”) to acquire Aardvark’s proprietary formulation, Delayed Burst Release Low Dose Naltrexone (DBR-LDN), or ARD-301, for the treatment of chronic pain, fibromyalgia, a ....

New York , United States , Jaisim Shah , Alexis Nahama , Tien Lee , Neda Faregh , Mary Ann Fitzcharles , Brian Johnson , Stephen Faraone , Scilex Holdings Company , Drug Administration , Department Of Psychiatry , National Fibromyalgia Association , Journal Of The American Medical Association , Health Related , Scilex Holding Company , Sorrento Therapeutics Inc , Scilex Holding , Therapeutics Inc , Pain Research , Scilex Pharmaceuticals Inc , Sorrento Therapeutics , Aardvark Therapeutics , Delayed Burst Release Low Dose Naltrexone , Long Haul , American Medical Association ,

NIH-funded study examines mono, chronic fatigue syndrome in college students


 E-Mail
Many college students fully recover from infectious mononucleosis (which is almost always caused by Epstein-Barr virus) within 1-6 weeks, but some go on to develop chronic fatigue syndrome, also called myalgic encephalomyelitis (ME/CFS). A longitudinal study from DePaul University and Northwestern University followed 4,501 college students to examine risk factors that may trigger longer illness. The research appears in the journal
Clinical Infectious Diseases and was funded by the National Institute of Allergy and Infectious Diseases.
Previous retrospective studies found that risk factors for developing ME/CFS after catching mono included preexisting physical symptoms and the number of days spent in bed, according to co-principal investigators Leonard A. Jason, professor of psychology at DePaul University; and Dr. Ben Z. Katz, a professor of pediatrics at Northwestern University Feinberg School of Medicine and a pediatric infectious disease specialist at Ann ....

Depaul Center , United States , Northwestern University , Depaul University , Joseph Colter , Madison Sunnquist , Benz Katz , Leonarda Jason , Mohammedf Islam , Ann Roberth Lurie , Vicky Whittemore , Stanley Manne Children Research Institute , Community Research At Depaul , National Institute Of Allergy , Northwestern University Feinberg School Of Medicine , Community Research , College Students Following Infectious Mononucleosis , Manne Research Institute , National Institute Of Neurological Disorders , Clinical Infectious Diseases , National Institute , Northwestern University Feinberg School , Program Director , Neurological Disorders , Prospective Cohort , Infectious Diseases ,